Silence Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of Underwriters Option to Purchase Additional ADSs
Silence Therapeutics plc, (Nasdaq: SLN), (Silence or the Company), a global clinical-stage biotechnology company developing novel short interfering RNA (siRNA) therapies, today announced the closing of its previously announced underwritten public offering of 14,907,407 American Depositary Shares...
Business Wire
Wall Street Analysts Predict a 140.06% Upside in Silence Therapeutics (SLN): Here's What You Should Know
The average of price targets set by Wall Street analysts indicates a potential upside of 140.1% in Silence Therapeutics (SLN). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Zacks
The Catalysts are Back: Socket Mobile Breaks Out While Biotechs Race Toward Major Milestones
Today's action is being driven by a potent combination of corporate catalysts, clinical readouts and investor anticipation, with Socket Mobile (NASDAQ:SCKT) emerging as one of the session's standout movers while biotech names AbCellera Biologics (NASDAQ:ABCL), Silence Therapeutics (NASDAQ:SLN) and NeOnc Technologies (NASDAQ:NTHI) command attention around major clinical milestones.
24-7 Market News
Silence Therapeutics Says Blood Cancer Trial Delivers 'Best-Case Outcome'
Silence Therapeutics reports positive Phase 2 SANRECO trial data for divesiran in polycythemia vera. Phase 3 trial planned for 1H 2027.read more...
Benzinga
Silence Therapeutics Announces Positive Topline Results from Phase 2 SANRECO Trial of Divesiran in Polycythemia Vera, Supporting its Potential Best-in-Class Profile
Silence Therapeutics plc (Nasdaq: SLN), a global clinical-stage biotechnology company developing novel siRNA (short interfering RNA) therapies, today announced positive topline results from the Phase 2 SANRECO trial of divesiran, a first-in-class siRNA, in 48 phlebotomy-dependent patients with...
Business Wire
Silence Therapeutics Hits the Catalyst Zone—Divesiran Data Could Send SLN Into Overdrive
Silence Therapeutics (NASDAQ:SLN) is heading into a potentially decisive moment as investors await topline results from the Phase 2 SANRECO trial of divesiran in polycythemia vera (PV). The company scheduled an August 10 conference call and webcast to discuss the results, putting its lead clinical program directly in the spotlight. With the Phase 2 study fully enrolled and topline data previously expected in the third quarter, the event represents a major potential inflection point for the clinical-stage biotech and its siRNA platform.
24-7 Market News
Silence Therapeutics Reports Second Quarter 2026 Financial and Business Results
Silence Therapeutics plc, (Nasdaq: SLN), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today reported its financial and business results for the second quarter ended June 30, 2026. Business Highlights Divesiran: First-in-class siRNA silencing TMPRSS6 for...
Business Wire
Silence Therapeutics shares surge ahead of divesiran Phase 2 results call
Silence Therapeutics shares surge ahead of divesiran Phase 2 results call...
Yahoo! Finance: News
Silence Therapeutics to Host Conference Call and Webcast to Discuss Topline Results from Phase 2 SANRECO Trial of Divesiran in Polycythemia Vera
Silence Therapeutics plc, (Nasdaq: SLN), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today announced a conference call and webcast to discuss topline results from the Phase 2 SANRECO trial of divesiran in polycythemia vera (PV) scheduled for tomorrow...
Business Wire
SLN Stock Skyrockets 107% in Six Months: Here's What You Need to Know
Silence Therapeutics shares surge as investors eye key 2026 divesiran data, an advancing RNAi pipeline and progress across multiple siRNA programs.
Zacks